TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

How anticoagulants may impact a patient’s risk of gastrointestinal bleeding after TAVR
Researchers tracked the rates of major gastrointestinal bleeding in patients with AFib randomized to receive edoxaban or a vitamin K antagonist after a successful TAVR procedure.
Boston Scientific pulls plug on TAVR devices after failing to gain FDA approval
After years of trying to catch up with the competition, Boston Scientific is moving on. The company is no longer seeking approval from the FDA or any other regulatory agencies for these devices, and all global sales have been discontinued.
Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards
Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.
Early TAVR or SAVR in asymptomatic patients linked to improved survival, reduced costs
Researchers explored data from more than 24,000 AVR patients, presenting their findings at EuroPCR in Paris.
Medtronic gains a key approval for Evolut TAVR valves
More patients can now undergo redo TAVR with a Medtronic valve than ever before.

AI model classifies patients by aortic stenosis severity, could improve AVR timing

The classifier was developed using imaging data from nearly 2,000 patients.

3 conditions associated with a higher stroke risk among TAVR patients

The new analysis, published in Current Problems in Cardiology, also explored the higher costs associated with post-TAVR stroke.

New meta-analysis examines valve durability after 5 years among TAVR, SAVR patients

As TAVR and SAVR patients get younger, valve durability will continue to gain more and more importance.

Edoxaban comparable to VKAs for treating AFib after TAVR

Researchers shared their findings at ESC Congress 2021 and in the New England Journal of Medicine.

Paravalvular leak after TAVR continues to be a problem—but advances in technology are helping

Additional studies are still necessary, but researchers are hopeful that modern TAVR solutions will help limit paravalvular leak in the years ahead.

Number of TAVR sites has nearly tripled in recent years—but quality issues remain

While the improved access is clearly beneficial, researchers did uncover potential issues that will need to be addressed.

New self-expanding TAVR system gains FDA approval

A full launch of the new system is scheduled for early 2022.

Repeat TAVR leads to better short-term outcomes than TAVR explantation

Repeat TAVR is expected to grow more and more common as time goes on, making it especially important to study its impact on patient outcomes.

TAVR

How anticoagulants may impact a patient’s risk of gastrointestinal bleeding after TAVR

Boston Scientific pulls plug on TAVR devices after failing to gain FDA approval

Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards

Early TAVR or SAVR in asymptomatic patients linked to improved survival, reduced costs

Medtronic gains a key approval for Evolut TAVR valves